Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIN-CoV-2
- Development stage
- Phase 1
- Lead developer
- Rokote Laboratories
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intranasal
01
Overview
FIN-CoV-2 is an intranasal COVID-19 vaccine candidate developed by Rokote Laboratories Finland Oy. It utilizes a replication-deficient adenovirus vector (Ad5) to deliver the genetic sequence of the SARS-CoV-2 spike protein directly to the mucous membranes of the respiratory tract. This approach is designed to induce both systemic immunity and local mucosal immunity (IgA), potentially blocking the virus at its point of entry and reducing transmission more effectively than intramuscular injections. The vaccine is based on research from the University of Eastern Finland and the University of Helsinki.
- Other names
- Rokote nasal vaccineRokote COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on FIN-CoV-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIN-CoV-2.